Henlius Prices Hong Kong IPO at the Bottom of the Range, Raising $410 Million
publication date: Sep 19, 2019
Shanghai Henlius Pharma raised $410 million in its Hong Kong IPO at a market cap of $2.9 billion, the low end of the range. The company is the majority-owned biologics subsidiary of Fosun Pharma. At the top end of the range, Henlius would have raised $477 million in its debut offering. Fosun and Henlius, a US company, formed the China biologics JV in 2010. In February, the company was approved for a China launch of a biosimilar to Roche's Rituxan, a lymphoma treatment. More details....
Stock Symbols: (HK: 2696) (SHA: 600196; HK: 2196)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.